LncRNA HULC regulates inflammation in vascular endothelial cells resulting in their dysfunction. Endothelial dysfunction contributes to severe COVID-19. lncRNA HULC targets miRNA-9 that play roles in the pathogenesis and progression of COVID-19 through the acute inflammatory response mediated by IL-6. This study aimed to evaluate the role of lncRNA HULC, miRNA-9, and IL-6 in estimating the severity and predicting the prognosis of COVID-19. There were 38 non-severe, 38 severe COVID-19 patients, and 38 healthy controls enrolled in this study. Expression of lncRNA HULC and miRNA-9 was performed using RT-qPCR. ELISA was utilized to measure serum IL-6. Expression of lncRNA HULC and IL-6 level were increased in severe patients compared to non-severe patients and controls (p < 0.001). MiRNA-9 showed the lowest expression levels in the severe patients in comparison with non-severe patients and controls (p < 0.001) lncRNA HULC was negatively correlated with miRNA-9 (p < 0.001, r = −0.582) and positively correlated with IL-6 (p < 0.001, r = 0.567). Furthermore, miRNA-9 showed a negative correlation with IL-6 (p < 0.001, r = −0.0466). For severity prediction, lncRNA HULC expression had an adjusted OR of 52.5 (95% CI: 1.43−192.2, p = 0.031). The lncRNA HULC had an adjusted mortality hazard ratio of 1.9 (95% CI: 1.02−3.56, p = 0.043) after the adjustment of IL-6. So, in COVID-19 patients, the lncRNA HULC had a positive correlation with IL-6 and a negative correlation with miRNA-9. The COVID-19 severity and mortality appear to be predicted independently by the lncRNA HULC.
Citation: Marwa M. Esawy, Amir Abd-elhameed, Alshimaa L. Abdallah, Maha E. Alsadik, Elsayed S. Abd elbaser, Marwa A. Shabana, Rania M. Abdullah. Long noncoding RNA HULC is an independent predictor of COVID-19 severity and mortality in relation to microRNA-9 and IL-6[J]. AIMS Molecular Science, 2022, 9(2): 79-90. doi: 10.3934/molsci.2022005
LncRNA HULC regulates inflammation in vascular endothelial cells resulting in their dysfunction. Endothelial dysfunction contributes to severe COVID-19. lncRNA HULC targets miRNA-9 that play roles in the pathogenesis and progression of COVID-19 through the acute inflammatory response mediated by IL-6. This study aimed to evaluate the role of lncRNA HULC, miRNA-9, and IL-6 in estimating the severity and predicting the prognosis of COVID-19. There were 38 non-severe, 38 severe COVID-19 patients, and 38 healthy controls enrolled in this study. Expression of lncRNA HULC and miRNA-9 was performed using RT-qPCR. ELISA was utilized to measure serum IL-6. Expression of lncRNA HULC and IL-6 level were increased in severe patients compared to non-severe patients and controls (p < 0.001). MiRNA-9 showed the lowest expression levels in the severe patients in comparison with non-severe patients and controls (p < 0.001) lncRNA HULC was negatively correlated with miRNA-9 (p < 0.001, r = −0.582) and positively correlated with IL-6 (p < 0.001, r = 0.567). Furthermore, miRNA-9 showed a negative correlation with IL-6 (p < 0.001, r = −0.0466). For severity prediction, lncRNA HULC expression had an adjusted OR of 52.5 (95% CI: 1.43−192.2, p = 0.031). The lncRNA HULC had an adjusted mortality hazard ratio of 1.9 (95% CI: 1.02−3.56, p = 0.043) after the adjustment of IL-6. So, in COVID-19 patients, the lncRNA HULC had a positive correlation with IL-6 and a negative correlation with miRNA-9. The COVID-19 severity and mortality appear to be predicted independently by the lncRNA HULC.
area under the ROC curve
Confidence interval
Coronavirus disease 2019
Highly upregulated in liver cancer
Interleukin-6
Long noncoding RNA (lncRNA)
miRNA
Receiver Operator Characteristic
Reverse transcription
Quantitative real-time polymerase chain reaction
[1] | Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 |
[2] | Wiersinga WJ, Rhodes A, Cheng AC, et al. (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. Jama 324: 782-793. https://doi.org/10.1001/jama.2020.12839 |
[3] | Ponti G, Maccaferri M, Ruini C, et al. (2020) Biomarkers associated with COVID-19 disease progression. Critical reviews in clinical laboratory sciences 57: 389-399. https://doi.org/10.1080/10408363.2020.1770685 |
[4] | Yu Y, Liu T, Shao L, et al. (2020) Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study. Virulence 11: 1569-1581. https://doi.org/10.1080/21505594.2020.1840108 |
[5] | Panzitt K, Tschernatsch MM, Guelly C, et al. (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132: 330-342. https://doi.org/10.1053/j.gastro.2006.08.026 |
[6] | Yu X, Zheng H, Chan MT, et al. (2017) HULC: an oncogenic long non-coding RNA in human cancer. J of cellular and molecular medicine 21: 410-417. https://doi.org/10.1111/jcmm.12956 |
[7] | Hernández-Romero IA, Guerra-Calderas L, Salgado-Albarrán M, et al. (2019) The Regulatory Roles of Non-coding RNAs in Angiogenesis and Neovascularization from an Epigenetic Perspective. Frontiers in oncology 9: 1091. https://doi.org/10.3389/fonc.2019.01091 |
[8] | Jayasuriya R, Ganesan K, Xu B, et al. (2022) Emerging role of long non-coding RNAs in endothelial dysfunction and their molecular mechanisms. Biomed Pharmacother 145: 112421. https://doi.org/10.1016/j.biopha.2021.112421 |
[9] | Ruhl L, Pink I, Kühne JF, et al. (2021) Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal transduction and targeted therapy 6: 418. https://doi.org/10.1038/s41392-021-00819-6 |
[10] | Chen Y, Fu Y, Song YF, et al. (2019) Increased Expression of lncRNA UCA1 and HULC Is Required for Pro-inflammatory Response During LPS Induced Sepsis in Endothelial Cells. Front Physiol 10: 608. https://doi.org/10.3389/fphys.2019.00608 |
[11] | Coomes EA, Haghbayan H (2020) Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol 30: 1-9. https://doi.org/10.1002/rmv.2141 |
[12] | Huang Z, Zhou JK, Peng Y, et al. (2020) The role of long noncoding RNAs in hepatocellular carcinoma. Molecular cancer 19: 77. https://doi.org/10.1186/s12943-020-01188-4 |
[13] | Amini-Farsani Z, Yadollahi-Farsani M, Arab S, et al. (2021) Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways. International immunopharmacology 100: 108071. https://doi.org/10.1016/j.intimp.2021.108071 |
[14] | Rostamian A, Ghazanfari T, Arabkheradmand J, et al. (2020) Interleukin-6 as a Potential Predictor of COVID-19 Disease Severity in Hospitalized Patients and its Association with Clinical Laboratory Routine Tests. Immunoregulation 3: 29-36. http://dx.doi.org/10.32598/Immunoregulation.3.1.4 |
[15] | Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408. https://doi.org/10.1006/meth.2001.1262 |
[16] | Wu Y, Zhao T, Deng R, et al. (2021) A study of differential circRNA and lncRNA expressions in COVID-19-infected peripheral blood. Scientific reports 11: 7991. https://doi.org/10.1038/s41598-021-86134-0 |
[17] | Ma Y, Huang D, Yang F, et al. (2016) Long noncoding RNA highly upregulated in liver cancer regulates the tumor necrosis factor-alpha-induced apoptosis in human vascular endothelial cells. DNA Cell Biol 35: 296-300. https://doi.org/10.1089/dna.2015.3203 |
[18] | Fodor A, Tiperciuc B, Login C, et al. (2021) Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19-Mechanisms and Therapeutic Targets. Oxidative medicine and cellular longevity 2021: 8671713. https://doi.org/10.1155/2021/8671713 |
[19] | Gavriilaki E, Eftychidis I, Papassotiriou I (2021) Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics. Journal of Laboratory Medicine 45: 293-302. https://doi.org/10.1515/labmed-2021-0134 |
[20] | Khan MA, Sany M, Islam MS, et al. (2020) Epigenetic Regulator miRNA Pattern Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 World-Wide Isolates Delineated the Mystery Behind the Epic Pathogenicity and Distinct Clinical Characteristics of Pandemic COVID-19. Frontiers in genetics 11: 765. https://doi.org/10.3389/fgene.2020.00765 |
[21] | Cui M, Xiao Z, Wang Y, et al. (2015) Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res 75: 846-857. https://doi.org/10.1158/0008-5472.CAN-14-1192 |
[22] | Yi J, Gao ZF (2019) MicroRNA-9-5p promotes angiogenesis but inhibits apoptosis and inflammation of high glucose-induced injury in human umbilical vascular endothelial cells by targeting CXCR4. Int J Biol Macromol 30: 1-9. https://doi.org/10.1016/j.ijbiomac.2019.02.003 |
[23] | Zhang J, Jia J, Zhao L, et al. (2016) Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Mol Carcinog 55: 732-742. https://dx.doi.org/10.1002%2Fmc.22317 |
[24] | Wang Y, Han Z, Fan Y, et al. (2017) MicroRNA-9 inhibits NLRP3 inflammasome activation in human atherosclerosis inflammation cell models through the JAK1/STAT signaling pathway. Cell Physiol Biochem 41: 1555-1571. https://doi.org/10.1159/000470822 |
[25] | Shen Y, Xue C, You G, et al. (2021) miR-9 alleviated the inflammatory response and apoptosis in caerulein-induced acute pancreatitis by regulating FGF10 and the NF-κB signaling pathway. Exp Ther Med 22: 795. https://doi.org/10.3892/etm.2021.10227 |
[26] | Catanzaro M, Fagiani F, Racchi M (2020) Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction and Targeted Therapy 5: 84. https://doi.org/10.1038/s41392-020-0191-1 |
[27] | Vatansever HS, Becer E (2020) Relationship between IL-6 and COVID-19: to be considered during treatment. Future Virology 15: 817-822. https://doi.org/10.2217/fvl-2020-0168 |
[28] | Condrat CE, Thompson DC, Barbu MG, et al. (2020) miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 9: 276. https://doi.org/10.3390/cells9020276 |
[29] | Wang WT, Ye H, Wei PP, et al. (2016) LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol 3: 117. https://doi.org/10.1186/s13045-016-0348-0 |
[30] | Wang H, Feng Q, Wu Y, et al. (2021) Association of circulating long non-coding RNA HULC expression with disease risk, inflammatory cytokines, biochemical index levels, severity-assessed scores, and mortality of sepsis. J Clin Lab Anal 35: e23656. https://doi.org/10.1002/jcla.23656 |
[31] | Chen ZL, Chen YX, Zhou J, et al. (2020) LncRNA HULC alleviates HUVEC inflammation and improves angiogenesis after myocardial infarction through down-regulating miR-29b. Eur Rev Med Pharmacol Sci 24: 6288-6298. https://doi.org/10.26355/eurrev_202006_21527 |
[32] | Chu P, Wang Q, Wang Z, et al. (2019) Long non-coding RNA highly up-regulated in liver cancer protects tumor necrosis factor-alpha-induced inflammatory injury by down-regulation of microRNA-101 in ATDC5 cells. Int Immunopharmacol 72: 148-158. https://doi.org/10.1016/j.intimp.2019.04.004 |
[33] | Liang H, Li F, Li H, et al. (2021) Overexpression of lncRNA HULC Attenuates Myocardial Ischemia/reperfusion Injury in Rat Models and Apoptosis of Hypoxia/reoxygenation Cardiomyocytes via Targeting miR-377-5p through NLRP3/Caspase‑1/IL‑1β Signaling Pathway Inhibition. Immunol Invest 50: 925-938. https://doi.org/10.1080/08820139.2020.1791178 |
[34] | Grifoni E, Valoriani A, Cei F, et al. (2020) Interleukin-6 as prognosticator in patients with COVID-19. The Journal of infection 81: 452-482. https://doi.org/10.1016/j.jinf.2020.06.008 |
[35] | Tang J, Lin J, Zhang E, et al. (2021) Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients. Medicine 100: e26131. https://doi.org/10.1097/MD.0000000000026131 |
[36] | Li C., Hu X., Li L., et al. (2020) Differential microRNA expression in the peripheral blood from human patients with COVID-19. J of clinical laboratory analysis 34: e23590. https://doi.org/10.1002/jcla.23590 |
[37] | Farr RJ, Rootes CL, Rowntree LC, et al. (2021) Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog 17: e1009759. https://doi.org/10.1371/journal.ppat.1009759 |
[38] | de Gonzalo-Calvo D, Benítez ID, Pinilla L, et al. (2021) Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Translational research 236: 147-159. https://doi.org/10.1016/j.trsl.2021.05.004 |
[39] | Morenikeji OB, Bernard K, Strutton E, et al. (2021) Evolutionarily Conserved Long Non-coding RNA Regulates Gene Expression in Cytokine Storm During COVID-19. Frontiers in bioengineering and biotechnology 8: 582953. https://doi.org/10.3389/fbioe.2020.582953 |
[40] | Fernández-Pato A, Virseda-Berdices A, Resino S, et al. (2022) Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. Emerging microbes & infections 11: 676-688. https://doi.org/10.1080/22221751.2022.2038021 |
[41] | Liu X, Wang H, Shi S, et al. (2021) Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. Postgrad Med J 2021: 139939. https://doi.org/10.1136/postgradmedj-2021-139939 |
[42] | El-Shabrawy M, Alsadik ME, El-Shafei M, et al. (2021) Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egypt J Bronchol 15: 5. https://doi.org/10.1186/s43168-021-00054-1 |
[43] | Talwar D, Kumar S, Acharya S, et al. (2022) Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. Indian J Crit Care Med 26: 39-42. https://doi.org/10.5005/jp-journals-10071-24075 |